Literature DB >> 32111587

A Novel Tail-Associated O91-Specific Polysaccharide Depolymerase from a Podophage Reveals Lytic Efficacy of Shiga Toxin-Producing Escherichia coli.

Yibao Chen1,2, Xiangmin Li1,2,3,4, Shuang Wang1,2, Lingyu Guan1,2, Xinxin Li1,2, Dayue Hu1,2, Dongyang Gao1,2, Jiaoyang Song1,2, Huanchun Chen1,2,3,4, Ping Qian5,2,3,4.   

Abstract

Shiga toxin-producing Escherichia coli (STEC) strains are important zoonotic foodborne pathogens, causing diarrhea, hemorrhagic colitis, and life-threatening hemolytic uremic syndrome (HUS) in humans. However, antibiotic treatment of STEC infection is associated with an increased risk of HUS. Therefore, there is an urgent need for early and effective therapeutic strategies. Here, we isolated lytic T7-like STEC phage PHB19 and identified a novel O91-specific polysaccharide depolymerase (Dep6) in the C terminus of the PHB19 tailspike protein. Dep6 exhibited strong hydrolase activity across wide ranges of pH (pH 4 to 8) and temperature (20 to 60°C) and degraded polysaccharides on the surface of STEC strain HB10. In addition, both Dep6 and PHB19 degraded biofilms formed by STEC strain HB10. In a mouse STEC infection model, delayed Dep6 treatment (3 h postinfection) resulted in only 33% survival, compared with 83% survival when mice were treated simultaneously with infection. In comparison, pretreatment with Dep6 led to 100% survival compared with that of the control group. Surprisingly, a single PHB19 treatment resulted in 100% survival in all three treatment protocols. Moreover, a significant reduction in the levels of proinflammatory cytokines was observed at 24 h postinfection in Dep6- or PHB19-treated mice. These results demonstrated that Dep6 or PHB19 might be used as a potential therapeutic agent to prevent STEC infection.IMPORTANCE Shiga toxin-producing Escherichia coli (STEC) is an important foodborne pathogen worldwide. The Shiga-like toxin causes diarrhea, hemorrhagic colitis, and life-threatening hemolytic uremic syndrome (HUS) in humans. Although antibiotic therapy is still used for STEC infections, this approach may increase the risk of HUS. Phages or phage-derived depolymerases have been used to treat bacterial infections in animals and humans, as in the case of the "San Diego patient" treated with a phage cocktail. Here, we showed that phage PHB19 and its O91-specific polysaccharide depolymerase Dep6 degraded STEC biofilms and stripped the lipopolysaccharide (LPS) from STEC strain HB10, which was subsequently killed by serum complement in vitro In a mouse model, PHB19 and Dep6 protected against STEC infection and caused a significant reduction in the levels of proinflammatory cytokines. This study reports the use of an O91-specific polysaccharide depolymerase for the treatment of STEC infection in mice.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  O91-specific polysaccharide depolymerase; Shiga toxin-producing Escherichia colizzm321990; bacteriophage; infection; therapy

Year:  2020        PMID: 32111587     DOI: 10.1128/AEM.00145-20

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  13 in total

1.  Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Jiawei Bai; Feiyang Zhang; Shuang Liang; Qiao Chen; Wei Wang; Ying Wang; Alberto J Martín-Rodríguez; Åsa Sjöling; Renjing Hu; Yingshun Zhou
Journal:  Front Cell Infect Microbiol       Date:  2022-07-05       Impact factor: 6.073

Review 2.  Biological foundations of successful bacteriophage therapy.

Authors:  Carola Venturini; Aleksandra Petrovic Fabijan; Alicia Fajardo Lubian; Stefanie Barbirz; Jonathan Iredell
Journal:  EMBO Mol Med       Date:  2022-05-27       Impact factor: 14.260

3.  Bursting out: linking changes in nanotopography and biomechanical properties of biofilm-forming Escherichia coli to the T4 lytic cycle.

Authors:  Shiju Abraham; Yair Kaufman; François Perreault; Ry Young; Edo Bar-Zeev
Journal:  NPJ Biofilms Microbiomes       Date:  2021-03-17       Impact factor: 7.290

Review 4.  Bacteriophage-Derived Depolymerases against Bacterial Biofilm.

Authors:  Gracja Topka-Bielecka; Aleksandra Dydecka; Agnieszka Necel; Sylwia Bloch; Bożena Nejman-Faleńczyk; Grzegorz Węgrzyn; Alicja Węgrzyn
Journal:  Antibiotics (Basel)       Date:  2021-02-10

5.  Isolation, characterization and application of bacteriophage PSDA-2 against Salmonella Typhimurium in chilled mutton.

Authors:  Ziyu Sun; Hui Wen; Li Ma; Zhongjun Chen
Journal:  PLoS One       Date:  2022-01-24       Impact factor: 3.240

6.  Characterization and Food Application of the Novel Lytic Phage BECP10: Specifically Recognizes the O-polysaccharide of Escherichia coli O157:H7.

Authors:  Do-Won Park; Jong-Hyun Park
Journal:  Viruses       Date:  2021-07-27       Impact factor: 5.048

7.  Phage-Derived Depolymerase as an Antibiotic Adjuvant Against Multidrug-Resistant Acinetobacter baumannii.

Authors:  Xi Chen; Miao Liu; Pengfei Zhang; Miao Xu; Weihao Yuan; Liming Bian; Yannan Liu; Jiang Xia; Sharon S Y Leung
Journal:  Front Microbiol       Date:  2022-03-25       Impact factor: 5.640

Review 8.  Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing Escherichia coli.

Authors:  Su-Bin Hwang; Ramachandran Chelliah; Ji Eun Kang; Momna Rubab; Eric Banan-MwineDaliri; Fazle Elahi; Deog-Hwan Oh
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

Review 9.  AB5 Enterotoxin-Mediated Pathogenesis: Perspectives Gleaned from Shiga Toxins.

Authors:  Erika N Biernbaum; Indira T Kudva
Journal:  Toxins (Basel)       Date:  2022-01-16       Impact factor: 4.546

Review 10.  Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.

Authors:  Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak; Stephen T Abedon
Journal:  Antibiotics (Basel)       Date:  2021-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.